BlackRock Inc. grew its position in Evolus Inc (NASDAQ:EOLS) by 12.2% during the 2nd quarter, Holdings Channel reports. The fund owned 994,396 shares of the company’s stock after buying an additional 107,946 shares during the quarter. BlackRock Inc.’s holdings in Evolus were worth $14,540,000 as of its most recent filing with the Securities & Exchange Commission.
Several other large investors have also recently modified their holdings of the company. MetLife Investment Advisors LLC purchased a new stake in Evolus during the first quarter worth about $115,000. Metropolitan Life Insurance Co NY purchased a new stake in Evolus during the first quarter worth about $83,000. Valeo Financial Advisors LLC boosted its holdings in Evolus by 52.1% during the second quarter. Valeo Financial Advisors LLC now owns 7,300 shares of the company’s stock worth $107,000 after buying an additional 2,500 shares in the last quarter. Edge Wealth Management LLC purchased a new stake in Evolus during the second quarter worth about $29,000. Finally, Segantii Capital Management Ltd purchased a new stake in Evolus during the second quarter worth about $1,097,000. 19.20% of the stock is currently owned by institutional investors and hedge funds.
Shares of EOLS opened at $15.20 on Friday. The company has a current ratio of 5.01, a quick ratio of 4.51 and a debt-to-equity ratio of 1.87. The stock has a market cap of $414.45 million, a P/E ratio of -9.68 and a beta of 4.75. The company has a 50-day moving average of $15.98 and a two-hundred day moving average of $17.77. Evolus Inc has a 12-month low of $10.22 and a 12-month high of $30.25.
EOLS has been the topic of a number of research analyst reports. JMP Securities decreased their price objective on shares of Evolus from $35.00 to $30.00 and set a “market outperform” rating on the stock in a report on Tuesday, August 13th. They noted that the move was a valuation call. Wells Fargo & Co initiated coverage on shares of Evolus in a report on Friday, June 28th. They set a “market perform” rating and a $16.00 price objective on the stock. ValuEngine downgraded shares of Evolus from a “buy” rating to a “hold” rating in a report on Tuesday. Mizuho reissued a “buy” rating and set a $30.00 price objective on shares of Evolus in a report on Thursday, September 5th. Finally, Stifel Nicolaus set a $33.00 price objective on shares of Evolus and gave the stock a “buy” rating in a report on Wednesday, July 31st. One investment analyst has rated the stock with a sell rating, three have given a hold rating and six have issued a buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $26.67.
Evolus Company Profile
Evolus, Inc, a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.
Read More: Bond
Want to see what other hedge funds are holding EOLS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Evolus Inc (NASDAQ:EOLS).
Receive News & Ratings for Evolus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolus and related companies with MarketBeat.com's FREE daily email newsletter.